Journal article
The emerging role of lapatinib in HER2-positive breast cancer
Current oncology reports, v 10(1), pp 10-17
Jan 2008
PMID: 18366956
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.
Metrics
Details
- Title
- The emerging role of lapatinib in HER2-positive breast cancer
- Creators
- Alice Ulhoa-Cintra - Allegheny General HospitalLarisa GreenbergCharles E Geyer - Allegheny General Hospital
- Publication Details
- Current oncology reports, v 10(1), pp 10-17
- Publisher
- Springer Nature
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- General Internal Medicine
- Web of Science ID
- WOS:000207841800004
- Scopus ID
- 2-s2.0-38149058790
- Other Identifier
- 991021931092204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology